We want to make effective treatment optimization accessible to every European citizen
U-PGx: UBIQUITOUS PHARMACOGENOMICS
THE “PREPARE” CLINICAL STUDY
PHARMACOGENOMICS EDUCATIONAL MATERIAL
Pharmacogenomics (PGx) is the study of genetic variability affecting an individual’s response to a drug. Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.
The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).
50% of elderly patients will receive drug treatment that could be optimized via PGx within the next four years.
98% of physicians think that PGx could help to better predict drug response.
Lack of knowledge
Only 10% of physicians feel they currently have adequate knowledge and tools for PGx.
September 29th, 2020 was a memorable day as Cristina Lucía Dávila Fajardo obtained her (second!) PhD degree from Leiden University in the Netherlands. Since 2010, she collaborates with Prof. Henk-Jan Guchelaar and Dr. Jesse Swen from the Leiden University Medical Center in pharmacogenetics research.
On September 2nd, 2020 Cathelijne van der Wouden obtained her PhD degree from Leiden University in the Netherlands. She started her PhD in 2016 in the research group of Prof. Henk-Jan Guchelaar and Dr. Jesse Swen from the Leiden University Medical Center.
As per October 1st 2018, the PREPARE study sites have crossed-over to the opposite arm! Since then, more than 2,500 patients have been enrolled in the PREPARE study.
The 3rd U-PGx Personalized Medicine Public Day was successfully co-organized in Patras, Greece by the Golden Helix Foundation together with the University of Patras, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy (Patras, Greece).
A practice paper “Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts” analysing educational needs to develop pharmacogemomics from science to patient care and about our U-PGx perspective was recently published in Clinical Pharmacology & Therapeutics.
One of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use.
WP8 of the U-PGx project provides an Ethical, Legal and Societal Implications (ELSI) expertise and education on ethical and legal aspects regarding Pharmacogenomics (PGx).
To genotype or not to genotype – that’s the question. DPWG provides recommendations for pre-emptive genotyping
In the PREPARE study participants are genotyped pre-emptively, but what to do for all other patients? Can you initiate therapy without pre-emptive testing or is genotyping necessary for specific drugs?
The 6th U-PGx Personalized Medicine Day will be organized in Athens, Greece on December 13th, 2019.